TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3526155
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (cephalothin, gentamicin, and carbenicillin)
Study: 31907104
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment only (M)
Study: 31179007
Drug: 3-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day antibiotic treatment
Study: 31050078
Drug: 7-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day antibiotic treatment
Study: 28681388
Drug: Natalizumab (NTZ)
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab (NTZ) treatment
Study: 21316267
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1000 mg/day
Study: 21316267
Drug: Carbamazepine-CR (CBZ-CR)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine-CR (CBZ-CR) 400 mg/day
Study: 15295223
Drug: PncCRM vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PncCRM vaccine
Study: 9683300
Drug: oral clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral clodronate 1600 mg daily for 3 years
Study: 2962321
Drug: Heparin 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5,000 International units per liter added to warm isotonic Ringer's lactate solution
Study: 2962321
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin added to warm isotonic Ringer's lactate solution
Study: 23761104
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion of 30 g/150 mL water plus 3 g 3‐O‐methylglucose (3‐OMG)
Study: 23761104
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion of 30 g/150 mL water plus 3 g 3‐OMG
Study: 22164503
Drug: Routine liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine liver protection drugs
Study: 19407949
Drug: Auricular points
Normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auricular points sticking-pressing (APSP), pellets pressed 4 times daily
Study: 7781464
Drug: Atropine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (7 micrograms/kg) during active gas infusion
Study: 7781464
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during active gas infusion
Study: 7781464
Drug: Sham gas
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham gas administration
Study: 7781464
Drug: Active gas
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active gas infusion
Study: 2146577
Drug: Ondansetron 3
Normalized name: ondansetron 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 3 x 8 mg/day for a maximum of 10 cycles
Study: 356241
Drug: Proquazone (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proquazone (900 mg daily)
Study: 28527564
Drug: Peri- and
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri- and postoperative antibiotic prophylaxis (POAP) from the day of operation until the fifth day postoperatively
Study: 28527564
Drug: Perioperative antibiotic
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotic prophylaxis (PEAP) only
Study: 28527564
Drug: Perioperative antibiotic
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotic prophylaxis and increased local antiseptic care (PAPAC)
Study: 24350597
Drug: Moderate-dose endurance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose endurance training (MOD, 300 kcal/day)
Study: 24350597
Drug: High-dose endurance
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose endurance training (HIGH, 600 kcal/day)
Study: 20455886
Drug: Cholecalciferol (60,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (60,000 IU D3/week for 8 weeks followed by 60,000 IU/month for 4 months) with 1 g of elemental calcium daily
Study: 16239760
Drug: Olanzapine (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (exact dosage and duration not specified)
Study: 10463251
Drug: Iprazochrome 15
Normalized name: iprazochrome
DrugBank: Iprazochrome (DB13541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iprazochrome 15 mg daily in three equal doses for eight weeks
Study: 9017568
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of treatment on a fee-for-service basis
Study: 9017568
Drug: Transfer to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer to another treatment provider
Study: 6685516
Drug: Piretanide 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide 12 mg
Study: 25222799
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (Coping Cat) for 12 weeks
Study: 25222799
Drug: Medication (sertraline)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (sertraline) for 12 weeks
Study: 25222799
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cognitive-behavioral treatment and medication for 12 weeks
Study: 25222799
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo for 12 weeks
Study: 16529161
Drug: Renal replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal replacement therapy (haemodialysis) with polysulphone membranes
Study: 11387733
Drug: Clinician-Administered PTSD
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-Administered PTSD Scale (CAPS)
Study: 31913927
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg ketamine
Study: 30009223
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg ketamine
Study: 24508795
Drug: Cross-linking twice
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cross-linking twice (Group B)
Study: 18207016
Drug: Modified-release prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release prednisone tablet taken at bedtime, released with a delay of 4 hours after ingestion.
Study: 18207016
Drug: Immediate-release prednisone
Normalized name: prednisone Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release prednisone tablet taken in the morning as an active comparator.
Study: 18207016
Drug: Immediate-release prednisone
Normalized name: prednisone Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release prednisone
Study: 15688278
Drug: Recombinant HIV-1
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HIV-1 envelope glycoprotein subunit (rgp120) vaccine
Study: 10774461
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with methotrexate (MTX)
Study: 29026977
Drug: PVP (PROCEED®
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVP (PROCEED® Ventral Patch)
Study: 25192498
Drug: Dersalazine sodium
Normalized name: mesalazine
DrugBank: Dersalazine (DB06251)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dersalazine sodium 1200 mg/12 h
Study: 25192498
Drug: Mesalazine 1200
Normalized name: mesalamine 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 1200 mg/12 h
Study: 21524314
Drug: High fiber,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fiber, relatively high carbohydrate diet (50% carbohydrate, > 35 g total dietary fiber, 20% protein)
Study: 17062305
Drug: Sustained-release glipizide
Normalized name: glipizide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release glipizide (GSR) 10 mg PO QD
Study: 17062305
Drug: Immediate-release glipizide
Normalized name: glipizide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release glipizide (GIR) 5 mg PO BID
Study: 17062305
Drug: Sustained-release glipizide
Normalized name: glipizide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release glipizide (GSR)
Study: 17062305
Drug: Immediate-release glipizide
Normalized name: glipizide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release glipizide (GIR)
Study: 10880063
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care preparation for child's BMT
Study: 8918625
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron saccharate (10-100 mg)
Study: 8918625
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron saccharate (100 mg)
Study: 8918625
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron saccharate (10-40 mg)
Study: 1417433
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (alone or in combination with medication)
Study: 1417433
Drug: Imipramine hydrochloride
Normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine hydrochloride pharmacotherapy
Study: 1417433
Drug: Combined cognitive-pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cognitive-pharmacotherapy
Study: 1819153
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet (40 mg frusemide and 5 mg amiloride)
Study: 1391258
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no diuretics)
Study: 24380874
Drug: Behavioural voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural voice therapy
Study: 24380874
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (after eight week assessment)
Study: 20384746
Drug: Tamoxifen tablets
Normalized name: tamoxifen Oral Tablet
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen tablets postoperatively according to a standard protocol
Study: 16061590
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg, once daily)
Study: 16061590
Drug: Fluticasone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (100 microg, twice daily)
Study: 2180658
Drug: Tofu-based frozen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofu-based frozen dessert (TFD) containing high-fructose corn syrups
Study: 2180658
Drug: Dairy-based sucrose-sweetened
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dairy-based sucrose-sweetened ice cream (IC)
Study: 19957871
Drug: Pool-aquatic program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pool-aquatic program in warm water (three weekly 60-min sessions for four months)
Study: 12852237
Drug: Chemotherapy (drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (drugs such as cyclophosphamide, 5-fluorouracil, and doxorubicin)
Study: 28941196
Drug: Vortioxetine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (single rising doses)
Study: 28941196
Drug: Vortioxetine (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (multiple doses)
Study: 22277837
Drug: Chemotherapy (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (standard docetaxel or pemetrexed regimens)
Study: 20729242
Drug: Adjuvant temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant temozolomide alone (150 mg/m²/day, 7/14‐day schedule)
Study: 20729242
Drug: Adjuvant temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant temozolomide plus thalidomide (400 mg/day)
Study: 20729242
Drug: Adjuvant temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant temozolomide plus isotretinoin (100 mg/m²/day)
Study: 20729242
Drug: Adjuvant temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant temozolomide plus celecoxib (400 mg twice daily)
Study: 20729242
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (dose-dense temozolomide with cytostatic agents)
Study: 11534926
Drug: Imipramine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine maintenance treatment (IMI-IMI)
Study: 11534926
Drug: Placebo maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo maintenance treatment (PBO-PBO)
Study: 3065737
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) 400 mg/kg body weight every 3 weeks for a year
Study: 29794557
Drug: Ibudilast (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibudilast (50 mg bid)
Study: 23532241
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg daily) for 12 months
Study: 23532241
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg daily)
Study: 18433945
Drug: Glutamate ingestion
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate ingestion (30 mg/kg BW)
Study: 18433945
Drug: Control ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control ingestion (1.25 ml/kg BW)
Study: 10718783
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg once daily for 8 days
Study: 3886340
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg orally each morning)
Study: 3886340
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg orally twice daily)
Study: 22057829
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) 10 ppm followed by sildenafil 100 mg orally 30 minutes later
Study: 22057829
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg orally followed by inhaled nitric oxide (iNO) 10 ppm 60 minutes later
Study: 19821509
Drug: Teduglutide 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide 0.2 mg/kg daily
Study: 19821509
Drug: Teduglutide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide 0.1 mg/kg daily
Study: 19821509
Drug: Teduglutide 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide 0.05 mg/kg daily
Study: 19821509
Drug: Teduglutide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide 0.1 mg/kg daily (open-label phase)
Study: 19821509
Drug: Teduglutide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide (all doses)
Study: 17432690
Drug: Compound Shiwei
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Shiwei Tablet (CST)
Study: 17432690
Drug: Sanjin Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanjin Tablet (ST)
Study: 15367305
Drug: Pamidronate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (60 mg as a single dose)
Study: 8996853
Drug: Pellet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pellet formulation (R)
Study: 28644104
Drug: Benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 30 mg every 8 weeks (first three doses every 4 weeks)
Study: 26148133
Drug: Low-dose creatine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose creatine supplementation (acute and chronic)
Study: 26148133
Drug: High-dose creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose creatine supplementation (acute and chronic)
Study: 25098088
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of injection Celfuroxime 1.5 gm at the time of induction of anaesthesia (Group A)
Study: 25098088
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic (Group B)
Study: 19092349
Drug: Methylprednisolone treatment
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone treatment (250 mg at consent, followed by 100 mg/h infusion)
Study: 17159174
Drug: Indometacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (75 mg) sustained release once daily for six weeks
Study: 17159174
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for six weeks
Study: 7054760
Drug: Hydrocortisone hemisuccinate,
Normalized name: Hydrocortisone Hemisuccinate, hemisuccinate compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone hemisuccinate, 50 mg/kg body weight
Study: 29052033
Drug: Perturbation-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perturbation-based therapy (random-perturbation exercise, 13 weeks, 2 times per week, 1.5 hours per session)
Study: 21237718
Drug: Triple antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiretroviral prophylaxis (300 mg zidovudine, 150 mg lamivudine, and 400 mg lopinavir plus 100 mg ritonavir twice daily until cessation of breastfeeding, maximum 6.5 months postpartum)
Study: 21237718
Drug: Zidovudine and
Normalized name: zidovudine and lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine and single-dose nevirapine (300 mg zidovudine twice daily until delivery, 600 mg zidovudine plus 200 mg nevirapine at onset of labour, and after protocol amendment, 300 mg zidovudine twice daily and 150 mg lamivudine twice daily for 1 week postpartum)
Study: 19373709
Drug: Psychoanalytic psychotherapy
Normalized name: PSYCHOANALEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytic psychotherapy (once‐ or twice‐weekly for 4‐12 months)
Study: 17766660
Drug: Docetaxel (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (single agent)
Study: 11432768
Drug: Micronutrient and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient and single cell oil supplement containing docosahexaenoic acid
Study: 7996818
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment with artificial tears
Study: 21359920
Drug: Electro-acupuncture combined
Normalized name: combinations of electrolytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture combined with Fluoxetine
Study: 21359920
Drug: Fluoxetine only
Normalized name: Fluoxetine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine only (Control)
Study: 21191332
Drug: Splat Oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Splat Oral Care Foam 2 in 1
Study: 17701405
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg PO omeprazole (young subjects)
Study: 17701405
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg IV omeprazole (young subjects)
Study: 17701405
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg IV omeprazole (elderly subjects)
Study: 16393158
Drug: Pregabalin flexible
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin flexible dose (150 and 300 mg/day for 2 weeks each; 450 and 600 mg/day for 4 weeks each, BID)
Study: 16393158
Drug: Pregabalin fixed
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin fixed dose (600 mg/day BID)
Study: 16393158
Drug: Pregabalin fixed
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin fixed dose vs flexible dose
Study: 16393158
Drug: Pregabalin flexible
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin flexible dose
Study: 16393158
Drug: Pregabalin fixed
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin fixed dose
Study: 8653534
Drug: Orlistat 360
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 360 mg per day
Study: 220536
Drug: Interferon (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (administered for six weeks starting on the day of transplantation)
Study: 27702806
Drug: 1.25% fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25% fluoride gel application
Study: 21536191
Drug: Heavy rotational
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy rotational force (225 g)
Study: 21536191
Drug: Light rotational
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light rotational force (25 g)
Study: 21536191
Drug: Compression areas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression areas (buccal‐distal and lingual‐mesial surfaces)
Study: 15663094
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (CDDP+FU, TAX+FU, CDDP)
Study: 15663094
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment only (Control group)
Study: 3111702
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 3 mg dihydroergocristine and 100 mg levo‐5‐hydroxytryptophan
Study: 27498100
Drug: Bilastine 50
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Bilastine 50 mg